Fas (CD95) and its ligand are central regulatory molecules in hematopoietic cells. Previous studies have suggested a role for Fas in the regulation of tumor progression, but Fas has not yet been conclusively identified as a tumor suppressor. Fas-deficient individuals lack mahgnant tumors, perhaps because of regulation by T cells. To investigate such a possibility, mice deficient in both T cells and Fas were generated, and they were found to develop severe B cell dysregulotion characterized by malignant, lethal B cell lymphoma. Lymphoma arose from a monoclonal B220+CD19-CD5-CD23 -B cell secreting immunoglobulin M, K rheumatoid factor. In contrast, animals containing ~x]3 T cells, y8 T cells, and/or functional Fas suppressed the development of lymphoma. These data indicate that Fas functions as a tumor suppressor, and identifies roles for both or]3 T cells and y8 T cells in Fas-independent tumor regulation.
C
entral regulators of immune responses include Fas (CD95) and its ligand. Activated lymphocytes upregulate Fas, rendering themselves susceptible to apoptosis upon interaction with ceils expressing Fas ligand (1) . The central importance of these molecules is illustrated by Fasdeficient mice and humans, who have defective peripheral lymphocyte tolerance because of an inability to complete activation-induced cell death (2) (3) (4) (5) . These regulatory interactions may involve both T and B cells (6, 7) .
Such findings suggest that Fas deficiency promotes lymphoid tumor development. Indeed, a regulatory role for Fas in tumor progression has been suggested by its altered expression on some human cancers (8) , and the allelic loss of chromosome 10@3, to which Fas maps (9) , in prostate (10), brain (11) ,. skin (12) , endometrial (13) , and lymphoid (14) malignancies. Defects in Fas alone, however, do not induce malignancy, causing instead a nonmalignant lymphoproliferation ofCD3+CD4-CD8 -T cells in both mice and humans (3, 15, 16) . While B cell "tumors" have been described in Fas-deficient Ipr mice on the SJL background, which itself develops B cell hyperplasias, these polyclonal populations resemble mature t3 cells and are not malignant (17) . Instead, the absence of functional Fas promotes pathological B cell hyperactivity resulting in T cell-dependent autoantibody production and systemic autoimmune disease This paper is based partially upon a dissertation submitted by S.L. Peng to fulfill in part the requirements for the degree of Doctor of Philosophy from Yale University. (18) . Thus, while Fas deficiency clearly causes lymphocyte dysregulation, it alone does not result in malignant transformation.
As one explanation of these findings, Fas-deficient tumors in situ may be regulated by T cells, which have previously been shown to reject experimental tumors (19) . To test this hypothesis, T cell-deficient Ipr mice were developed and observed. Such mice spontaneously developed intraabdominal B cell lymphoma with significant associated mortality. In contrast, animals possessing et]3 T cells, ",/8 T cells, and/or functional Fas suppressed lymphoma development. Thus, Fas functions as a tumor suppressor, and both ot[3 and ~/8 T cells regulate lymphoma progression.
(7.0 kb) and targeted (3.1 kb) alleles. Fas genotype was determined by PCR as described previously (20) . All mice, homozygotic at all three loci, were raised under specific pathogen-free conditions at the Yale University School of Medicine.
Pathology. Lethal V(D)J Sequencing. Genomic DNA was isolated from whole tissue by proteinase K/phenol extraction. P C R was performed with AmpliTaq ~ in a GeneAmp 9600 (Perkin-Elmer Corp., Norwalk, CT) at 94~ 30 s; 60~ 1 rain; 72~ 1 rain for 35 cycles. Forward primers included VH7183F (5'-GAAGTGAAGCTGGT-GGAGTCTGGGGGAG) and VHJ558F (5'-GAGGTCCAG-CTGCAGCAGTCTGGACCTG); reverse primers includedJH4R (5'-CTGAGGAGACGGTGACTGAGGTI'CCTTG) or JH4INR (5'-CAGGCTCCACCAGACCTCTCTAGA) (21) . Control primers for the wild-type TCR-ot locus have been described elsewhere (20) . PCR products were cloned by the TA Cloning | Kit (Invitrogen, San Diego, CA) and sequenced by Sequenase TM Version 2.0 (U.S. Biochemical Corp., Cleveland, OH).
Antibody Assays. Serum IgM was determined by an ELISA Ig isotyping kit (Pierce Chemical Co., Rockford, IL); for inhibition, the serum equivalent of 100 I.tg IgM was preincubated with 1 mg total mouse IgG (Southern) at 37~ for 1 h. Data reflect either lymphoma-free or lymphoma-afflicted T cell-deficient lpr animals. Serum K rheumatoid factor was determined as described (22) . Statistical significance was evaluated by unpaired Student's t test.
Results and Discussion
T cell-deficient, Fas-deficient animals developed intraabdominal lymphoid malignancy with associated mortality at a penetrance of at least 70% ( Figs. 1 and 2 ). Affected mice possessed severe hepatosplenomegaly and malignant, exudative ascites ( Fig. 1 and data not shown) . Such animals cal lpr-induced infiltrates in the liver and kidney were pleomorphic (Fig. 2 E) and involved only 5-10% of involved organs, in contrast to the widespread infiltration seen in lymphoma-bearing animals. PCR analysis of genomic DNA revealed that the lymphomas were restricted to the expression of a V~558-JH4 heavy chain rearrangement: other common V(D)J rearrangements were not detected, including VH7183-JH 1, JH2, J.3, orJ.4, as well as vHj558-jH1, JH2, orJH3 (Fig. 4 A and data not shown). Monoclonality was verified by sequence analysis of PCR products, which demonstrated identical V(D)J rearrangements among several PCR. clones from the lymphoma, but variable rearrangements among PCR clones from the wild-type spleen (Fig. 4 B) . The presence of an A---)G mutation among the clones in one lymphoma may reflect oligoclonality, but the presence of identical V-D and D-Jjoins of the same V, D, andJ regions strongly suggests that these sequences represent mutations within a single clone caused by AmpliTaq error or perhaps somatic mutation (23) . These lymphomas secreted an IgM, K rheumatoid factor, as evidenced by severe elevations in serum IgM that could be inhibited by competitive mouse IgG (Fig. 4 C; P <0.001), as well as elevated serum K rheumatoid factor (Fig. 4 D and data not shown; P <0.001).
Lethal lymphoma was observed in the majority of oq3, y5 T cell-deficient lpr mice ("-'60-70% by 7 mo of age), but was partially penetrant in T cell-deficient, Fas-intact animals (,'-'10% by 7 mo of age; Figs. 1 and 4 E; P <0.01). Accordingly, these findings demonstrate a tumor suppressor function for Fas and a regulatory role for el]3 and for ",/8 T cells in tumorigenesis. Since lymphoma was suppressed in Ipr animals containing either T cell but lacking functional Fas, these results strongly suggest that both types ofT cells may regulate B cell lymphoma via a Fas-independent mechanism. This may involve perforin or other Fasindependent cytotoxic mechanisms (19) that are activated by MHC/peptide complexes (24) or nonpeptide ligands (25) . Alternatively, T cells may circumvent the need for Fas-dependent regulation by inducing terminal differentiation, as seen in the reduction of myc-induced lymphomas by the induction of B cell differentiation (26) . Still, Fas is directly implicated in the regulation of this lymphoma since T cell-intact, Fas-intact animals developed malignancy at a significantly decreased penetrance compared to T cell-deficient lpr counterparts. Fas may affect tumorigenesis by interacting directly with other tumor suppressor genes like p53 (27) , or protooncogenes like bcl-2 (28). These studies seem germane to the development of B cell lymphoma in acquired immune deficiency syndrome, where chronic antigen stimulation may substitute for Fas deficiency in promoting a pool of premalignant B cells that progress to malignancy in the absence ofT cell regulation (29) .
